Incyte Corp. buy stratec
Start price
19.02.20
/
50%
€75.44
Target price
04.11.21
€100.00
Performance (%)
-22.53%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The prediction for Incyte Corp. disappointed with a performance of -22.53%. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Incyte Corp. | -3.086% | -3.086% | -26.249% | -28.066% |
iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |
Comments by stratec for this prediction
In the thread Incyte Corp. diskutieren
Incyte (NASDAQ:INCY) perks up 2% premarket on light volume on the heels of its announcement of positive results from a second Phase 3 clinical trial, TRuE-AD1, evaluating ruxolitinib cream 0.75% or 1.5% in patients at least 12 years old with mild-to-moderate atopic dermatitis (AD). The study met the primary endpoint of a statistically significant proportion of treated patients achieving clear or almost clear skin at week 8 compared to vehicle (placebo). A sister Phase 3, TRuE-AD2, was also successful. Marketing applications should be the next step.
Kursziel geändert auf 100,0
In the thread Trading Incyte Corp.
Die von stratec gewählte maximale Laufzeit wurde überschritten